Literature DB >> 31725511

Transthyretin Cardiac Amyloidosis as Diagnosed by 99mTc-PYP Scanning in Patients with Acute Heart Failure and Preserved Ejection Fraction.

Saberio Lo Presti1, Sofia A Horvath1, Christos G Mihos1, Chetan Rajadhyaksha2, Veronica McCloskey1, Orlando Santana1.   

Abstract

Transthyretin amyloid deposition is present in 17% of autopsies of patients with heart failure and a preserved ejection fraction (HFpEF). Technetium-pyrophosphate scintigraphy (Tc-PYP) is sensitive and specific to diagnose cardiac transthyretin amyloid deposition (ATTR). The prevalence of ATTR by Tc-PYP was evaluated along with echocardiographic parameters in patients with HFpEF. One-hundred consecutive patients with HFpEF, who had Tc-PYP, were retrospectively evaluated. Echocardiographic variables were analyzed to compare patients with positive versus negative ATTR infiltration. Myocardial ATTR was present in 19% of patients. Individuals with ATTR were older with a mean age of 82 ± 7 versus 75 ± 13 years (P = 0.03), had increased left ventricular hypertrophy with the interventricular septum measuring 1.6 (IQR, 1.4-2.0) versus 1.4 (IQR, 1.3-1.6) cm (P = 0.002), had a greater mean left ventricular mass index of 160 ± 50 g/m versus 131 ± 44 g/m (P = 0.01), and a reduced global longitudinal strain measuring -11% (IQR, -9 to -12) versus -12% (IQR, -10 to -16), P = 0.04. The prevalence of ATTR myocardial deposition demonstrated by Tc-PYP in patients with HFpEF is comparable to that of autopsy studies. It is more common in older patients, with increased left ventricular hypertrophy and reduced global longitudinal strain.

Entities:  

Year:  2019        PMID: 31725511     DOI: 10.1097/HPC.0000000000000183

Source DB:  PubMed          Journal:  Crit Pathw Cardiol        ISSN: 1535-2811


  6 in total

Review 1.  A systematic review and meta-analysis of the prevalence of transthyretin amyloidosis in heart failure with preserved ejection fraction.

Authors:  Mohamed Magdi; Mostafa Reda Mostafa; Waiel Abusnina; Ahmad Al-Abdouh; Ramy Doss; Sarah Mohamed; Chidera Philippa Ekpo; Richard Alweis; Bipul Baibhav
Journal:  Am J Cardiovasc Dis       Date:  2022-06-15

2.  The use of PYP scan for evaluation of ATTR cardiac amyloidosis at a tertiary medical centre.

Authors:  Joshua Dower; Danai Dima; Mumtu Lalla; Ayan R Patel; Raymond L Comenzo; Cindy Varga
Journal:  Br J Cardiol       Date:  2022-05-31

3.  Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience.

Authors:  Omar K Siddiqi; Yuliya Y Mints; John L Berk; Lawreen Connors; Gheorghe Doros; Deepa M Gopal; Shivangi Kataria; Graham Lohrmann; Alexandra R Pipilas; Frederick L Ruberg
Journal:  Amyloid       Date:  2022-01-27       Impact factor: 6.571

Review 4.  Estimating the Gender Distribution of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis.

Authors:  Florint Kroi; Nils Fischer; Ana Gezin; Mahmoud Hashim; Mark Hermannes Rozenbaum
Journal:  Cardiol Ther       Date:  2020-12-14

5.  Left ventricular mass index-to-QRS-voltage ratio predicts outcomes in heart failure with preserved ejection fraction.

Authors:  Yoshiharu Kinugasa; Kensuke Nakamura; Hiroko Kamitani; Masayuki Hirai; Kiyotaka Yanagihara; Masahiko Kato; Toshiyuki Nagai; Tsutomu Yoshikawa; Yoshihiko Saito; Yasuchika Takeishi; Kazuhiro Yamamoto; Toshihisa Anzai
Journal:  ESC Heart Fail       Date:  2022-01-25

Review 6.  Transthyretin cardiac amyloidosis: a review of the nuclear imaging findings with emphasis on the radiotracers mechanisms.

Authors:  Teodor M Ionescu; Wael Jalloul; Cati R Stolniceanu; Roxana Iacob; Laura P Grecu; Ana-Maria Stătescu; Irena Grierosu; Mihai Guțu; Adrian Gavrilescu; Crișu Daniela; Antoniu Petriș; Manuela Ciocoiu; Cristina Ungureanu; Cipriana Ștefănescu
Journal:  Ann Nucl Med       Date:  2021-07-17       Impact factor: 2.668

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.